Norge - norsk - Statens legemiddelverk

orifarm healthcare a/s - klorheksidindihydroklorid / lidokainhydrokloridmonohydrat - sugetablett, komprimert med honningsmak - 5 mg / 1 mg

Norge - norsk - Statens legemiddelverk

orifarm healthcare a/s - klorheksidindihydroklorid / lidokainhydrokloridmonohydrat - sugetablett, komprimert med jordbærsmak - 5 mg / 1 mg

Norge - norsk - Statens legemiddelverk

orifarm healthcare a/s - klorheksidindihydroklorid / lidokainhydrokloridmonohydrat - sugetablett, komprimert med mentolsmak - 5 mg / 1 mg

Norge - norsk - Statens legemiddelverk

orifarm healthcare a/s - klorheksidindihydroklorid / lidokainhydrokloridmonohydrat - sugetablett, komprimert med sitronsmak - 5 mg / 1 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.